trending Market Intelligence /marketintelligence/en/news-insights/trending/Tbx_nZ2zw-AmGNx-crFWJg2 content esgSubNav
In This List

Nippon Shinyaku secures rights to 2 Jazz Pharmaceuticals treatments

Case Study

Identifying PPE Suppliers During the Pandemic


Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage


COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021


Corporate Credit Risk Trends in Developing Markets: A Loss Given Default (LGD) Perspective

Nippon Shinyaku secures rights to 2 Jazz Pharmaceuticals treatments

Nippon Shinyaku Co. Ltd. secured the rights to develop and commercialize Jazz Pharmaceuticals PLC's Defitelio and Vyxeos treatments in Japan.

Jazz will receive an upfront payment for granting Nippon Shinyaku the rights, as well as future consideration once certain regulatory and commercial milestones are met. Nippon Shinyaku will also pay Jazz Pharmaceuticals a royalty on the sale of the drugs.

Neither of the drugs is approved for sale in Japan.

Defitelio, which is already approved in the U.S., is meant to treat adult and pediatric patients with the hepatic veno-occlusive disease as a result of renal or pulmonary dysfunction following hematopoietic stem-cell transplantation.

Hepatic veno-occlusive disease is a condition in which some of the small veins in the liver are obstructed.

Vyxeos is being investigated for the treatment of acute myeloid leukemia, a type of blood cancer. Jazz Pharmaceuticals plans to seek U.S. and European approval for the treatment this year.